Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $1,161 from $1,163 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q4 results following checks with investor relations and recent management commentary.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO)
- Structure Therapeutics moved to Buy rating at Goldman Sachs
- Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 18
- Eli Lilly’s New Dulaglutide Study Targets Real-World Safety Questions for GLP-1 Investors